[{"id":"fd9a6ef1-e63d-48f1-a37f-74e055c7f2e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05672459","created_at":"2023-01-05T14:58:32.705Z","updated_at":"2025-02-25T14:09:22.292Z","phase":"Phase 1/2","brief_title":"A Safety and Efficacy Study of HLA-G- Targeted CAR-T Cells IVS-3001 in Subjects with Previously Treated Advanced HLA-G-Positive Solid Tumors","source_id_and_acronym":"NCT05672459","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • BRCA • HLA-G","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA • HLA-G"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • IVS-3001"],"overall_status":"Recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 06/21/2023","start_date":" 06/21/2023","primary_txt":" Primary completion: 06/29/2026","primary_completion_date":" 06/29/2026","study_txt":" Completion: 12/29/2029","study_completion_date":" 12/29/2029","last_update_posted":"2025-01-20"}]